概述
Evidence must match the context of use and the consequences of error. A promising retrospective model is not automatically credible for a clinical or regulatory decision.
主要要点
- State context of use and endpoint.
- Use risk-based validation and multidisciplinary review.
- Manage the model across its lifecycle.
深入探讨
Define the intended use, population, endpoint, and decision boundary. A model prioritizing compounds for laboratory study differs from one used to inform a clinical submission. Preserve the distinction between exploratory hypotheses and evidence used to support safety or effectiveness. Use documented data provenance, quality controls, and appropriate validation. Check batch effects, missing measurements, site differences, and whether the outcome label is a meaningful proxy. For time-dependent or prospective decisions, use evaluation data that respects when information becomes available. FDA and EMA guiding principles emphasize human-centered design, risk-based approaches, context of use, multidisciplinary expertise, data governance, performance assessment, and lifecycle management. Treat these as a framework for evidence and accountability, not as a blanket approval of a model. Retain versioned protocols, model outputs, and review decisions. Monitor performance after deployment and define how a change in data, assay, or model triggers reassessment.
04工作示例
Move from discovery to evidence carefully
Imagine a model ranking ten compounds for laboratory testing with a strong retrospective score.
Before using it for a patient-safety decision, define the prospective endpoint and evaluate on data collected under that protocol.
Record the uncertainty and require domain review at the new decision boundary.
它显示了什么
The constructed example separates exploratory prioritization from regulated evidence.
现实世界的实施
Hold out a study site when evaluating whether a biomarker model transfers.
Document context of use before using an AI result in a regulated submission.
付诸实践
为什么这很重要
- 背景与规则. 行业背景决定了人工智能创意能否与现实接触。
- 质量控制. 领域约束会影响可接受的错误率和监督模型。
- 构建选择. 成功的部署使技术能力与一线工作流程保持一致。
留意
- 监管要求可能会使原本强大的原型失效。
- 历史数据可能会编码损害特定社区的偏见。
- 遗留系统可能会造成集成瓶颈和隐性成本。
后续步骤
- 让领域专家参与从问题框架到评估的整个过程。
- 在启动前设计审计跟踪和文档。
- 尽早验证合规性和安全义务。
- 分阶段推出，并具有明确的停止和回滚标准。
资料来源与延伸阅读
不断探索
常见问题
Does a strong discovery benchmark prove clinical credibility?
No. Evidence requirements depend on the intended use, data, endpoint, and risk of the decision.